The SBIR/STTR funding landscape for life-science companies

Federal agency comparison

The Department of War (DoW, formerly referred to as DoD) has the largest program in the SBIR.gov directory. HHS, principally through NIH, has the broadest relevance to biomedical companies. Other agencies support narrower applications of biotechnology.

Need help with your next funding decision? Assess funding fit and readiness.

Source: SBIR.gov participating agencies.

Fit ratings are an editorial assessment for human biomedical companies. They are not agency eligibility determinations. EPA’s funding page lists no open solicitation, but was last updated in 2025.

NIH budgets: the guideline is not the ceiling

NIH’s general budget guidelines are $323,090 for Phase I and $2,153,927 for Phase II. Institute-specific limits under approved SBA waivers can be substantially higher. The current parent announcement lists the following limits; eligibility depends on the institute and approved topic.

These are limits, not typical award amounts. A larger request still needs a justified work plan. NIH’s Commercialization Readiness Pilot has a separate guideline of $4,191,495; Phase IIB limits depend on the opportunity.

Sources: NIH program basics and PA-27-100.

SBIR or STTR: the research structure matters

These are NIH requirements; agency rules can differ. NSF, for example, requires the principal investigator to be primarily employed by the company even for STTR. A university partnership is therefore a substantive operating decision, with implications for staffing, intellectual property, and where the funded work takes place.

Under NIH SBIR Phase I, third-party scientific and technical work normally cannot exceed 33% of total requested costs, including direct costs, indirect costs, and fee. On a $700,000 request, that is $231,000 across the relevant contracts and consultants. It is a limit on outsourced research, not a reserved advisory budget.

Sources: NIH SBIR parent announcement, NIH STTR parent announcement, NSF solicitation.

NIH application volume and success rates

These figures count competing applications reviewed and awards made, rather than all awards supported during the fiscal year. NIH’s FY2025 data also show substantial differences across mechanisms.

Source: NIH RePORT—Table 215, SBIR/STTR success rates. Percentages are shown to one decimal place. The rows total 8,915 applications and 931 awards, or 10.4%.

STTR Phase I’s 12.6% success rate was approximately 1.6 times SBIR Phase I’s 7.8%. For a company with a suitable research partner, this is a meaningful reason to assess STTR before defaulting to SBIR. It does not establish that changing mechanisms alone would produce that improvement: the applicant and project mix also differs.

STTR regular Phase II had the highest rate in the table, at 28.2%, but Phase II serves a different development stage and applicant population. Its rate is not an alternative probability available to a Phase I applicant.

Timing and commercialization support

The NIH parent announcement places the September 2026 submission cycle’s earliest start in April 2027—approximately seven months later. It accepts no late applications. NSF adds an earlier gate: a Project Pitch invitation is required before a Phase I or Fast Track proposal. Companies should budget for these steps before treating an award ceiling as available development capital.

NIH Technical and Business Assistance (TABA) can provide up to $6,500 for Phase I and $50,000 for Phase II, across the project period, for eligible commercialization activities. Requests need a justification and vendor identification where applicable. The April 2026 policy permits both application-stage requests and post-award administrative supplements; supplemental funding is not guaranteed. Commercialization Readiness Pilot awards are excluded.

Sources: NIH submission timetable, NSF Project Pitch requirements, NIH TABA policy.

Related non-dilutive funding pathways

The broader landscape includes federal and state programs outside conventional NIH SBIR/STTR. Some agencies also operate their own SBIR/STTR programs.

Sources: ARPA-H, BARDA DRIVe, CDMRP, CPRIT, CIRM.

Smaller programs can change the funding plan

USDA’s FY2025 Phase II announcement planned to fund approximately 45% of applications in each topic area. That was a funding target, not an observed award rate or evidence of the “best odds” across agencies. For an eligible agricultural biotechnology company, it nevertheless warrants attention alongside much larger programs. USDA FY2025 Phase II announcement.

For Houston and other Texas oncology companies, CPRIT merits a separate assessment alongside SBIR. Its Seed Company Award can provide up to $3 million. The FY2027 solicitation generally requires $1 in matching funds per $2 of CPRIT funding while cumulative CPRIT awards remain at or below $20 million; higher cumulative awards carry higher matching ratios. Companies based outside Texas may apply but must meet the specified Texas-presence criteria within one year of initial disbursement. Revenue-sharing terms also apply.

A combined CPRIT and SBIR plan should assign distinct costs and milestones to each award and establish an eligible source of matching funds. Neither overlapping reimbursement nor using federal funds as the match should be assumed. CPRIT FY2027 Seed Company Award solicitation.

Implications for funding strategy

Scientific fit and eligibility come first: a large agency budget or favorable historical rate has little value if the project cannot satisfy the program’s mission and research structure. Among eligible opportunities, however, competition is decision-relevant. NIH’s Phase I comparison makes STTR worth evaluating for companies with an appropriate institutional partner.

The next comparison is operational: how much work the award can fund, where that work must occur, and when funding could begin. A $700,000 ceiling, a seven-month minimum lead time, and an outsourcing limit affect different parts of the same development plan. Mechanism selection should precede proposal writing; the data do not quantify its value relative to proposal quality.